News · 26 weeks58-14%
2026-03-012026-08-23
Mix1590d
- SEC Filings8(53%)
- Offering3(20%)
- Other2(13%)
- Earnings1(7%)
- Analyst1(7%)
Latest news
25 items- ANALYSTInovio Pharma upgraded by Jefferies with a new price targetJefferies upgraded Inovio Pharma from Hold to Buy and set a new price target of $3.00
- SECInovio Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO Reports Second Quarter 2026 Financial Results and Recent Business HighlightsU.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026Commercial preparations advancing in anticipation of potential product launch for INO-3107Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in ChinaPresented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term
- SECSEC Form 10-Q filed by Inovio Pharmaceuticals Inc.10-Q - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inovio Pharmaceuticals Inc.SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
- PRINOVIO to Report Second Quarter Financial Results on August 12, 2026PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its second quarter 2026 financial results will be released after the market close on August 12th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.as
- SECSEC Form 8-K filed by Inovio Pharmaceuticals Inc.8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- SECSEC Form 424B5 filed by Inovio Pharmaceuticals Inc.424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO Announces Pricing of $20.0 Million Public OfferingPLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO al
- SECSEC Form 8-K filed by Inovio Pharmaceuticals Inc.8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- SECSEC Form 424B5 filed by Inovio Pharmaceuticals Inc.424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO Announces Proposed Public OfferingPLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to 15% of the shares of its common stock and/or accompanying
- SECSEC Form EFFECT filed by Inovio Pharmaceuticals Inc.EFFECT - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- SECSEC Form S-3 filed by Inovio Pharmaceuticals Inc.S-3 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
- PRINOVIO to Participate in Upcoming Scientific and Investor ConferencesPLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: Jefferies Global Healthcare Conference (New York) Date: Thursday, June 4 Time: 8:45 AM ET Format: Fireside Chat Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8 World Orphan Drug Congress (Boston) Poster P
- INSIDERSEC Form 4 filed by Director Yarno Wendy L4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Shepard Jay4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Miller Ann Calby4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Weiner David B.4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Zoth Lota S.4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Dansey Roger D4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERSEC Form 4 filed by Director Benito Simon X4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Scientific Officer Humeau Laurent converted options into 6,027 shares and covered exercise/tax liability with 2,163 shares, increasing direct ownership by 9% to 46,823 units (SEC Form 4) (for withholding tax)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Medical Officer Sumner Michael John converted options into 9,450 shares and covered exercise/tax liability with 2,693 shares, increasing direct ownership by 19% to 42,038 units (SEC Form 4) (for tax liability)4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
- INSIDERChief Executive Officer Shea Jacqueline Elizabeth converted options into 28,296 shares and covered exercise/tax liability with 12,306 shares, increasing direct ownership by 17% to 111,021 units (SEC Form 4) to satisfy withholding obligation4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
INO FAQ
6 questionsWhat does Inovio Pharmaceuticals Inc. do?
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines...Where does INO stock trade?
Inovio Pharmaceuticals Inc. (INO) is listed on NASDAQ.What sector and industry is INO in?
Inovio Pharmaceuticals Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about INO?
Inovio Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $300.00 price target on 2026-08-13.What companies are similar to INO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare INO side-by-side with any of them on Quantisnow.How can I track INO on Quantisnow?
Quantisnow aggregates Inovio Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INO to receive live email and push alerts on every new disclosure.